Brown Advisory’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-458,559
| Closed | -$58.8M | – | 1383 |
|
|
2025
Q2 | $58.8M | Sell |
458,559
-123,305
| -21% | -$12.8M | 0.08% | 176 |
|
|
2025
Q1 | $51.5M | Buy |
581,864
+3,084
| +0.5% | +$301K | 0.07% | 182 |
|
|
2024
Q4 | $50.5M | Sell |
578,780
-14,988
| -3% | -$1.37M | 0.06% | 207 |
|
|
2024
Q3 | $54.9M | Sell |
593,768
-24,224
| -4% | -$2.41M | 0.07% | 209 |
|
|
2024
Q2 | $66.6M | Sell |
617,992
-56,370
| -8% | -$5.64M | 0.09% | 168 |
|
|
2024
Q1 | $64M | Sell |
674,362
-5,558
| -0.8% | -$477K | 0.09% | 169 |
|
|
2023
Q4 | $62.7M | Buy |
679,920
+38,881
| +6% | +$2.52M | 0.09% | 170 |
|
|
2023
Q3 | $32.2M | Buy |
641,039
+5,843
| +0.9% | +$312K | 0.05% | 253 |
|
|
2023
Q2 | $40.1M | Buy |
635,196
+1,788
| +0.3% | +$97.2K | 0.06% | 225 |
|
|
2023
Q1 | $28.5M | Buy |
633,408
+32,126
| +5% | +$1.45M | 0.05% | 272 |
|
|
2022
Q4 | $26.3M | Sell |
601,282
-370,712
| -38% | -$17.8M | 0.05% | 278 |
|
|
2022
Q3 | $64M | Sell |
971,994
-23,275
| -2% | -$1.49M | 0.12% | 149 |
|
|
2022
Q2 | $50.3M | Buy |
995,269
+49,014
| +5% | +$2.87M | 0.09% | 173 |
|
|
2022
Q1 | $60.4M | Buy |
946,255
+70,000
| +8% | +$5.02M | 0.09% | 178 |
|
|
2021
Q4 | $93.9M | Buy |
876,255
+27,080
| +3% | +$2.83M | 0.12% | 125 |
|
|
2021
Q3 | $87.3M | Buy |
849,175
+53,317
| +7% | +$4.97M | 0.13% | 133 |
|
|
2021
Q2 | $70M | Buy |
795,858
+39,049
| +5% | +$3.58M | 0.11% | 160 |
|
|
2021
Q1 | $73.6M | Buy |
756,809
+20,176
| +3% | +$2.01M | 0.13% | 140 |
|
|
2020
Q4 | $82.6M | Buy |
736,633
+14,374
| +2% | +$1.51M | 0.15% | 119 |
|
|
2020
Q3 | $67M | Buy |
722,259
+10,783
| +2% | +$830K | 0.14% | 115 |
|
|
2020
Q2 | $55.5M | Buy |
711,476
+279,501
| +65% | +$18.9M | 0.13% | 127 |
|
|
2020
Q1 | $25.3M | Buy |
431,975
+54,602
| +14% | +$3.51M | 0.08% | 182 |
|
|
2019
Q4 | $30.2M | Buy |
377,373
+17,981
| +5% | +$1.35M | 0.08% | 198 |
|
|
2019
Q3 | $26.4M | Buy |
359,392
+85,048
| +31% | +$7.35M | 0.07% | 202 |
|
|
2019
Q2 | $25.9M | Buy |
274,344
+36,972
| +16% | +$3.05M | 0.07% | 218 |
|
|
2019
Q1 | $19M | Buy |
+237,372
| New | +$17.5M | 0.05% | 254 |
|
Other funds holding BPMC
IA
HNB
Brown Advisory's BPMC Position: Q3 2025 in Review
Brown Advisory sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 458,559 shares — an estimated $58.8M sold.
Brown Advisory first reported a position in BPMC in Q1 2019 and held it in 26 quarters. The position peaked at $93.9M in Q4 2021. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Brown Advisory reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Brown Advisory sold 458,559 Blueprint Medicines shares in Q3 2025, an estimated $58.8M.
- Brown Advisory first reported a position in Blueprint Medicines in Q1 2019 and held it in 26 quarters.
- Brown Advisory's Blueprint Medicines position peaked at $93.9M in Q4 2021.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Brown Advisory's 13F filing for Q3 2025, filed 14 Nov 2025.